


The burden of antimicrobial resistance (AMR) in Costa Rica

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **300 lives** have been lost each year since 1990 in Costa Rica due to AMR.
- In 2021, there were an estimated **386 UI (300-472)** deaths attributable to AMR and **1,650 UI (1,330-1,970)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **70+** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Staphylococcus aureus* resistant to methicillin, *Pseudomonas aeruginosa* resistant to carbapenems and *Streptococcus pneumoniae* resistant to carbapenems.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Costa Rica, a 10% reduction means to decrease the number of deaths associated with AMR to **1,540**, but currently the trend for this country could reach up to **2,040 UI [1,590-2,650]** AMR-associated deaths in 2030.

AMR in Costa Rica

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Costa Rica between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In **Costa Rica** in 2021, there were an estimated **386 UI (300-472)** deaths attributable to AMR and **1,650 UI (1,330-1,970)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **Costa Rica has the 41st lowest** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

Burden rank	Overall susceptible and resistant		Associated		Attributable	
	Staphylococcus aureus 649 UI (567-731)	↑	Staphylococcus aureus 395 UI (301-489)	↑	Staphylococcus aureus 111 UI (79-143)	↑
	Escherichia coli 420 UI (365-474)	↑	Escherichia coli 338 UI (286-390)	↑	Escherichia coli 60 UI (48-71)	↑
	Pseudomonas aeruginosa 347 UI (303-390)	↑	Streptococcus pneumoniae 176 UI (126-226)	↓	Acinetobacter baumannii 49 UI (40-58)	↑
	Klebsiella pneumoniae 319 UI (278-359)	↑	Pseudomonas aeruginosa 175 UI (136-215)	↑	Pseudomonas aeruginosa 46 UI (33-59)	↑
	Streptococcus pneumoniae 313 UI (275-350)	↓	Klebsiella pneumoniae 151 UI (111-190)	↑	Klebsiella pneumoniae 36 UI (27-45)	↑
	Acinetobacter baumannii 184 UI (161-207)	↑	Acinetobacter baumannii 138 UI (111-164)	↑	Streptococcus pneumoniae 33 UI (20-45)	↓
	Group A Streptococcus 98 UI (85-111)	↑	Enterococcus faecium 56 UI (45-66)	↑	Enterococcus faecium 11 UI (8-14)	↑
	Enterococcus faecalis 94 UI (81-106)	↑	Proteus spp. 46 UI (33-60)	↑	Enterobacter spp. 9 UI (7-11)	↑
	Enterococcus faecium 91 UI (79-102)	↑	Enterobacter spp. 38 UI (30-46)	↑	Serratia spp. 7 UI (5-8)	↑
	Proteus spp. 90 UI (78-101)	↑	Serratia spp. 29 UI (24-35)	↑	Proteus spp. 7 UI (4-9)	↑

Annualized rate of change (1990-2021) <-3% -3% to -1.5% -1.5% to 0% 0% to 1.5% 1.5% to 3% 3% to 5% >5.0%


Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)

Burden Rank	Associated			Attributable		
	Staphylococcus aureus Methicillin	334 UI (212-455)	↑	Staphylococcus aureus Methicillin	88 UI (57-118)	↑
	Escherichia coli Aminopenicillin	316 UI (242-390)	↑	Pseudomonas aeruginosa Carbapenems	24 UI (15-33)	↑
	Staphylococcus aureus Macrolides	255 UI (207-303)	↑	Streptococcus pneumoniae Carbapenems	17 UI (9-24)	↑
	Escherichia coli TMP-SMX	225 UI (169-280)	↑	Escherichia coli Aminopenicillin	16 UI (7-25)	↑
	Escherichia coli Fluoroquinolones	142 UI (92-192)	↑	Escherichia coli TMP-SMX	12 UI (7-18)	↑
	Escherichia coli Beta-Lactam/Lactamase Inhib.	119 UI (92-147)	↑	Acinetobacter baumannii Fluoroquinolones	12 UI (9-15)	↑
	Pseudomonas aeruginosa Carbapenems	119 UI (91-147)	↑	Klebsiella pneumoniae Fluoroquinolones	11 UI (7-15)	↑
	Staphylococcus aureus Fluoroquinolones	114 UI (83-145)	↑	Staphylococcus aureus Macrolides	11 UI (7-14)	↑
	Acinetobacter baumannii 3GC	112 UI (83-141)	↓	Acinetobacter baumannii Carbapenems	10 UI (6-14)	↑
	Pseudomonas aeruginosa Anti-pseudomonal	112 UI (80-145)	↑	Pseudomonas aeruginosa Anti-pseudomonal	9 UI (6-11)	↑

Annualized rate of change (1990-2021) <-3% -3% to -1.5% -1.5% to 0% 0% to 1.5% 1.5% to 3% 3% to 5% >5.0%

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) bloodstream infections (1,430 UI (1,250-1,620)), lower respiratory infection (excl. COVID) (1,430 UI (1,250-1,610)), peritoneal and intra-abdominal infections (553 UI (475-631)), urinary tract infections and pyelonephritis (414 UI (355-473)) and infections of the skin and subcutaneous systems (209 UI (179-239)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In Costa Rica, people aged 70+ saw the largest number of deaths associated with AMR both in 1990 and 2021, which indicates that 70+ continues to be particularly vulnerable to infections which are resistant to antibiotics. In 2021, the number of deaths associated with AMR among the 70+ was 916 UI (732-1,100), whereas the mortality rate per 100,000 was 292 UI (233-351).

Data sources for Costa Rica

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for Costa Rica by source type

Source type	Years	Sample size	Sample size units
Antibiotic use	2010-2021	131	Study-year datapoints
Microbial or laboratory data without outcome	2010-2021	65,225	Isolates
Microbial or laboratory data with outcome	1990-2021	408	Isolates
Single drug resistance profile data	1990-2021	27,785	Antibiotic susceptibility test

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care's Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>